This post was originally published on this site The Alzheimer’s Association and the African Methodist Episcopal Church (AME Church) announced a three-year partnership to promote greater involvement in the fight against Alzheimer’s (AD) and to heighten awareness of the support needed by patients and their families. Through the leadership of its International Health Commission, the AME…
This post was originally published on this site The European Commission has approved Darzalex (daratumumab), in combination with Revlimid (lenalidomide) and dexamethasone, as a first-line treatment for adults with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The decision was supported by the recent approval recommendation from the Committee for Medicinal Products for Human Use, an arm of the European…
This post was originally published on this site An advisory committee for the European Medicines Agency has recommended the conditional approval of Roche‘s Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) and bendamustine (a chemotherapy) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for a hematopoietic…
This post was originally published on this site Some of us are still adjusting to writing 2019 on bank checks, and here we are knocking on the door of the holidays. The older we become, the faster the years seem to zoom by. Just yesterday, we were children dreaming of snow at Christmas and our…
This post was originally published on this site The second part of a clinical study evaluating the use of a blood diagnostic test for Alzheimer’s disease — called the Lymphocyte Proliferation Test (LymPro Test) — is now fully enrolled, the trial’s sponsor, Breakthrough Diagnostics, announced. The trial is ongoing at Leipzig University in Germany, and top-line results are expected…
This post was originally published on this site The donor-derived, or allogeneic CAR T-cell therapy candidate UCARTCS1 has been administrated to the first patient in an ongoing Phase 1 trial for relapsed/refractory multiple myeloma. The study (NCT04142619), called MELANI-01, plans to enroll up to 18 adults whose multiple myeloma relapsed after prior treatment. It is…
This post was originally published on this site The National Institutes of Health (NIH) has awarded the Alzheimer’s Association $1.34 million to find more evidence-based ways to enhance care and support for those with Alzheimer’s disease (AD) or other dementias, and their care partners. The five-year grant will support a project titled “Leveraging an Interdisciplinary Consortium to…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted conditional approval to BeiGene’s Brukinsa (zanubrutinib) as a second-line treatment for adults with mantle cell lymphoma (MCL) who have received at least one prior therapy. According to BeiGene, the medication should become available to patients in the U.S. within…
This post was originally published on this site A team led by a University of Washington (UW) School of Medicine scientist will use a $17.2 million National Institute on Aging (NIA) grant to study whether degenerative eye diseases are linked to Alzheimer’s disease (AD). The award went to Cecilia Lee, an assistant professor of ophthalmology. Along…
This post was originally published on this site First-line maintenance therapy with Ninlaro (ixazomib) prolongs the time without disease progression in adults with multiple myeloma not treated with an autologous stem cell transplant, meeting its primary goal, data from a Phase 3 trial show. Ninlaro is an oral proteasome inhibitor marketed by Takeda. Proteasome inhibitors block…
